TearClear
is an ophthalmic pharmaceutical company that develops and commercializes drugs for the treatment of eye disorders... Read moreTearClear
is an ophthalmic pharmaceutical company that develops and commercializes drugs for the treatment of eye disorders... Read more
News
Sep 29, 2022
GlobalNewswire
Press Release: TearClear : TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)
Feb 07, 2022
FirstWord Pharma
TearClear: TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial
Sep 08, 2021
MarketScreener
TearClear: TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%
Mar 16, 2021
GlobeNewswire
Press Release: TearClear : TearClear Moving Toward Clinical Trials and Strengthening Leadership Team
Jan 06, 2021
South Florida Citybizlist
TearClear: Alachua's Life Sciences Ecosystem Raises Over $1.0 Billion in 2020
Dec 01, 2020
GlobalNewswire
Press Release: TearClear : TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma
Sep 29, 2020
Benzinga
TearClear: TearClear Appoints Robert Bailey to Board of Directors
Aug 25, 2020
Global University Venturing
TearClear: TearClear picks out $22m series B - Global University Venturing
Aug 12, 2020
FinSMEs
TearClear: TearClear Raises $22M in Series B Funding
May 07, 2020
PM360 Online
TearClear: Robert J. Dempsey joined TearClear as CEO
TearClear Competitors
1
2
3
4
5
6
7
8
9
10